tiprankstipranks
Aura Biosciences price target lowered to $25 from $30 at JMP Securities
The Fly

Aura Biosciences price target lowered to $25 from $30 at JMP Securities

JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Aura Biosciences to $25 from $30 and keeps an Outperform rating on the shares. Aura Biosciences is on track to begin dosing in its Phase 3 of AU-011 for primary choroidal melanoma in 1H23 with follow-on indications moving forward throughout the year, the analyst tells investors in a research note. Aura is also making progress in other indications with the first-in-human Phase 1 of AU-011 in bladder cancer on track for data in 2H23 and a Phase 1 for choroidal metastasis potentially starting around year-end, the firm adds.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AURA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles